Looking ahead to upcoming milestones, we expect to report phase one data for o five eight in the second half of this year, ...

Incyte Corporation INCY reported fourth-quarter 2025 adjusted earnings of $1.80 per share, which missed the Zacks Consensus Estimate of $1.94, primarily due to higher operating expenses. The company ...

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported in Q4 CY2025, with sales up 27.8% year on year to $1.51 ...

Incyte Corp (INCY) reports a 28% increase in Q4 revenue, driven by robust sales and strategic pipeline developments, while navigating competitive market pressures.

Investors in Incyte Corporation (Symbol: INCY) saw new options become available today, for the January 2027 expiration. One of the key inputs that goes into the price an option buyer is willing to pay ...

Investors in Incyte Corporation (Symbol: INCY) saw new options begin trading today, for the June 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is ...

Incyte Corporation (NASDAQ:INCY) is one of the most undervalued quality stocks to buy right now. On January 13, TD Cowen ...

In addition to Bank of America Securities, Incyte also received a Buy from TipRanks – xAI’s xAi Biotechnology in a report issued on January 24. However, on January 20, Wells Fargo downgraded Incyte ...

These data have been shared with the FDA, and Incyte will work closely with the FDA to determine the next steps. Also Read: Incyte’s Jakafi Demand Is Strong, Analyst Upgrades Stock Enrollment in the ...

Q4 2025 Earnings Call February 10, 2026 8:00 AM ESTCompany ParticipantsAlexis Smith - Vice President & Head of ...